Beljaro EZUSE – Tirzepatide – 10mg – Prefilled Pen (int) Beligas
€109.00
Overview of Beljaro EZUSE – Tirzepatide – 10mg – Prefilled Pen (int) Beligas, history and composition
Beljaro EZUSE – Tirzepatide – 10mg – Prefilled Pen (int) Beligas is an innovative pharmaceutical product designed for specific therapeutic interventions in metabolic health. Tirzepatide, the active ingredient, is a novel dual GIP and GLP-1 receptor agonist, aiming to enhance glucose metabolism and promote weight loss. The development of such agents comes at a time when obesity and related conditions are reaching epidemic proportions globally. The Beljaro EZUSE pen is specifically designed to deliver a precise dosage of 10mg, allowing for ease of use and accurate self-administration. The composition includes Tirzepatide as its primary component, along with various excipients to ensure stability and efficacy.
Physiological impact, what happens in the body
Upon administration, Tirzepatide acts on multiple physiological pathways. It improves insulin sensitivity, reduces glucagon secretion, and alters gastric emptying rates. These actions collectively contribute to lower blood sugar levels, substantial weight reduction, and improved metabolic health indicators. The drug stimulates the release of insulin in response to meals while also mimicking the effects of incretin hormones. This dual mechanism not only enhances glucose homeostasis but also significantly reduces appetite, making it a potent therapeutic option for individuals struggling with obesity. Users typically report increased satiety and reduced caloric intake over time, alongside increased energy levels and overall improved metabolic functioning.
How to acquire Beljaro EZUSE – Tirzepatide – 10mg – Prefilled Pen (int) Beligas, purchasing instructions
Acquiring Beljaro EZUSE requires navigating a few essential steps. It is crucial first to consult with a healthcare professional to confirm suitability. After receiving a prescription, individuals can purchase the prefilled pen at a licensed pharmacy or through legitimate online platforms that specialize in sports pharmacology products. Verification of the pharmacy’s credentials is advised to ensure that the product is authentic and safe. Always check for any ongoing promotions or bulk purchasing options, as some retailers may offer discounts for multiple pens, enhancing affordability.
Contraindications, who should avoid it
While Tirzepatide offers various benefits, certain individuals should exercise caution or avoid its use. Those with a history of severe allergic reactions to Tirzepatide or any of its components should not use this product. Additionally, people diagnosed with type 1 diabetes or those with diabetic ketoacidosis should avoid it, as well as individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Always consult a healthcare professional to discuss any existing health conditions, current medications, or potential interactions before starting treatment with Beljaro EZUSE.
Key effects, main reasons for use
Beljaro EZUSE is primarily utilized for its potent effects on weight management and metabolic health. The key reasons for its use include:
- Effectively lowering blood sugar levels
- Promoting significant weight loss
- Enhancing overall metabolic function
- Reducing appetite and promoting satiety
- Improving insulin sensitivity
Overall, the combination of these effects makes Tirzepatide a compelling option for individuals seeking to improve their health through weight loss and metabolic enhancement.
| Active substance | Tirzepatide |
|---|---|
| Hepatotoxicity | No significant hepatotoxicity reported |
| Lab Test | Monitoring blood glucose levels and HbA1c |
| Also known as | LY3298176 |
| Blood pressure | May reduce blood pressure |
| Trade name | Mounjaro |
| Storage conditions | Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F), protect from light |
| Chemical name | Tirzepatide |
| Formula | C225H348N48O68 |
| Substance class | Glucagon-like peptide-1 (GLP-1) receptor agonists |
| Main action | Lowers blood glucose levels |
| Half-life | Approximately 5 days |
| Dosage (medical) | Typically started at 2.5 mg once weekly, can be increased to 5 mg, 10 mg, or 15 mg once weekly depending on response and tolerability |
| Dosage (sports) | Not applicable as it is not used for performance enhancement |
| Effects | Improves glycemic control, promotes weight loss |
| Side effects | Nausea, diarrhea, decreased appetite, vomiting, constipation |
| Use in sports | None, not used for performance enhancement |
| Manufacturer | Beligas Pharmaceuticals |
| Packing | 10 mg (1 prefilled pen) |
| 5 |
|
0 |
| 4 |
|
0 |
| 3 |
|
0 |
| 2 |
|
0 |
| 1 |
|
0 |




Reviews
There are no reviews yet.